Kibow Biotech, Inc. to Present at BIO 2009 International Convention: Innovations to Heal, Fuel, and Feed...(status of development of the dietary sup...)

Date:5/14/2009

status of development of the dietary supplement formulation, Kibow Biotics(R), for kidney health in USA and the possibility of its approval as a drug in some other countries according to respective governmental authorities. Kibow is not a pharmaceutical company. Kibow products are not drugs and may not be considered as a treatment or a therapy. The dietary supplement formulation of Kibow Biotics will not cure, prevent or mitigate any disease. Actual results may differ significantly from the above forward-looking statements due to a number of factors including but not limited to the possibility that Kibow Biotics may not prove to be safe or show evidence of clinical activity in the current limited human trials or that data from patients enrolled in the study may not be useful or conclusive or sufficient to guide future development of Kibow Biotics. Other factors that could cause or contribute to differences in actual results include, but are not limited to, whether or not the Company or any of its collaborators will be able to develop dietary supplements using the technologies of the Company, risks associated with completing clinical trials of product candidates, the possibility that clinical testing may reveal to be undesirable and unintended side effects or other characteristics that may prevent or limit the commercial use of proposed products; whether the cash resources of the Company will be sufficient to fund operations as planned; reliance on key employees, especially senior management; the uncertainty of the Company's future access to capital; the risk that the Company may not secure or maintain relationships with collaborators, and the Company's dependence on intellectual property. The Company expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.

    For further information, contact:

    Natarajan Ranganathan, Ph.D.
    Interim CEO and Senior VP (R&D)
    Tel: 1 (610) 3
'/>"/>
SOURCE  Kibow Biotech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 
Related biology technology :

1. Kibow Biotech, Inc. Launches Breakthrough Probiotic Dietary Supplement for Kidney Health in USA and Canada
2. Kibow Biotech Strongly Supports World Kidney Day for Maintenance of Healthy Kidney Function
3. ALS Therapy Development Institute, the Worlds Largest Non-Profit Biotech, Appoints Steve Perrin, Ph.D., as Chief Executive Officer
4. Crystal Research Associates, LLC Issues an Executive Informational Overview(R) (EIO(R)) on ACT Biotech, Inc.
5. Ortho Biotech, L.P. and Centocor, Inc. Alert Authorized Distributors and Prescribing Physicians About Stolen Product
6. Lilly CEO Praises Massachusetts Leadership in Biotech, Urges Policy Prescriptions to Help Ensure States Investment Generates Dividends and Jobs
7. China Kangtai Cactus Biotech, Inc. Obtains $500,000 Equity Financing
8. Venture Capitalists Bullish on Greentech and Biotech, KPMG Study Says
9. China Kangtai Cactus Biotech, Inc. Reports Third Quarter 2007 Financial Results
10. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
11. PAREXEL Consulting Experts To Present Insights Into Achieving Regulatory Approval at the 2009 BIO International Convention